NCT07226427 A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
| NCT ID | NCT07226427 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Stemline Therapeutics, Inc. |
| Condition | Platinum-resistant Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-10 |
| Primary Completion | 2027-12-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 100 participants in total. It began in 2026-01-10 with a primary completion date of 2027-12-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Eligibility Criteria
Key Inclusion Criteria: * Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Key Exclusion Criteria: * Participants with primary platinum-refractory disease. Note: Other protocol-defined inclusion/exclusion criteria may apply.
Contact & Investigator
Stemline Trials
✉ cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com📞 1-877-332-7961
Medical Director
STUDY DIRECTOR
Stemline Therapeutics, Inc.
Frequently Asked Questions
Who can join the NCT07226427 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Platinum-resistant Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07226427 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07226427 currently recruiting?
Yes, NCT07226427 is actively recruiting participants. Contact the research team at cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com for enrollment information.
Where is the NCT07226427 trial being conducted?
This trial is being conducted at Springdale, United States, New Haven, United States, Sarasota, United States, Detroit, United States and 2 additional locations.
Who is sponsoring the NCT07226427 clinical trial?
NCT07226427 is sponsored by Stemline Therapeutics, Inc.. The principal investigator is Medical Director at Stemline Therapeutics, Inc.. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.